MedTrace Logo

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

NCT07589543 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-05-15

No results posted yet for this study

Summary

This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety/response follow-up.

Conditions

  • Epithelial Ovarian Cancer
  • Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum

Interventions

BIOLOGICAL

EB-DUALNK

(dual-target CAR-NK cells; selected antigen pair from GD2, MUC1, PSMA, mesothelin)

DRUG

Cyclophosphamide

lymphodepletion

DRUG

Fludarabine

lymphodepletion

Sponsors & Collaborators

  • Beijing Biotech

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2027-03-14
Completion
2028-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07589543 on ClinicalTrials.gov